A TLR8 agonist crystal form
By preparing the A crystal form of TLR8 agonist, the shortcomings of existing TLR8 agonists in agonism activity and specific selectivity were solved, effective application in the treatment of viral infections was achieved, and the auxiliary materials of the pharmaceutical composition were improved Its pharmaceutical properties ensure its effectiveness and safety in treatment.
Patent Information
- Application Number
- CN202180015947.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-03-18
- Filing Date
- 2021-03-18
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2041-03-18
AI Technical Summary
When existing TLR8 agonists activate the TLR8 signaling pathway, they are difficult to achieve ideal agonistic activity and specific selectivity, and there is a risk of immune hyperactivation, which affects their application in the treatment of viral infections such as hepatitis B.
Provide a crystal form of a TLR8 agonist, through specific compound structure and preparation methods, to ensure that it forms A crystal form under stirring conditions in a specific solvent, has significant TLR8 agonism activity and specific selectivity, and is in a pharmaceutical composition. Add appropriate excipients to improve their pharmacological properties.
It has achieved the ideal agonistic activity and specific selectivity of TLR8 agonists, has moderate oral bioavailability and drug exposure, supports oral administration, and has good physical and chemical stability, is suitable for use as a drug, and has industrial application value.
Smart Images

Figure CN115175906B_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority and benefits of Chinese Patent Application No. 202010193418.4 filed with the State Intellectual Property Office of China on March 18, 2020, and the contents disclosed in said application are incorporated herein by reference in their entirety. Technical Field
[0003] The present application belongs to the field of medicinal chemistry, and relates to a crystal form of a TLR8 (Toll-like receptor 8) agonist represented by formula (I) and a preparation method thereof, and also includes the use of the crystal form in the preparation of drugs for treating diseases responsive to TLR8 excitation. Background Art
[0004] Toll-like receptors (TLRs) are an important class of protein molecules involved in nonspecific immunity (natural immunity) and are also a bridge between nonspecific immunity and specific immunity. TLRs are single transmembrane non-catalytic proteins that are mainly expressed in a series of immune cells, such as dendritic cells, macrophages, monocytes, T cells, B cells, NK cells, etc. Toll-like receptors can recognize molecules with conservative structures derived from microorganisms. When microorganisms break through the body's physical barriers, such as skin and mucous membranes, TLRs can recognize them and activate the body to produce immune cell responses. For example, TLR1, -2, -4, -5 and -6 mainly recognize extracellular stimuli, such as bacterial lipopolysaccharides, lipopeptides, flagellar proteins, etc., while TLR3, -7, -8, and -9 act in cell endosomes, bind their ligands after engulfment and envelope dissolution, and can recognize microbial nucleic acids, etc.
[0005] Among the different subtypes of TLR, TLR8 has a unique function: TLR8 is mainly expressed in monocytes, macrophages and myeloid dendritic cells. The signaling pathway of TLR8 can be activated by bacterial single-stranded RNA, small molecule agonists and microRNAs. Activation of TLR8 leads to the production of Th1 polarity cytokines such as IL-12, IL-18, TNF-a and IFN-γ and various co-stimulatory factors such as CD80 and CD86. These cytokines can activate and amplify innate and adaptive immune responses and provide beneficial treatment options for diseases involving antiviral, anti-infection, autoimmunity, tumors, etc. For example, with regard to hepatitis B, activation of TLR8 on antigen-presenting cells and other immune cells in the liver can activate cytokines such as IL-12, thereby activating specific T cells and NK cells exhausted by the virus, thereby reconstructing antiviral immunity in the liver.
[0006] Application Contents
[0007] In one aspect, the present application provides a crystalline form of a compound of formula (I),
[0008]
[0009] In some embodiments of the present application, a crystalline form A of the compound of formula (I) is provided, and its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 10.50±0.20°, 20.72±0.20°, and 22.34±0.20°.
[0010] In some embodiments of the present application, the X-ray powder diffraction pattern of the above-mentioned crystal form A has characteristic diffraction peaks at the following 2θ angles: 8.86±0.20°, 10.50±0.20°, 11.38±0.20°, 17.80±0.20°, 20.72±0.20°, and 22.34±0.20°.
[0011] In some schemes of the present application, the X-ray powder diffraction pattern of the above-mentioned crystal form A has characteristic diffraction peaks at the following 2θ angles: 8.86±0.20°, 10.50±0.20°, 11.38±0.20°, 13.18±0.20°, 17.80±0.20°, 20.72±0.20°, 22.34±0.20°, and 26.86±0.20°.
[0012] In some schemes of the present application, the X-ray powder diffraction pattern of the above-mentioned crystal form A has characteristic diffraction peaks at the following 2θ angles: 8.86±0.20°, 10.50±0.20°, 11.38±0.20°, 13.18±0.20°, 16.48±0.20°, 17.80±0.20°, 20.36±0.20°, 20.72±0.20°, 22.34±0.20°, 24.42±0.20°, and 26.86±0.20°.
[0013] In some schemes of the present application, the X-ray powder diffraction pattern of the above-mentioned crystal form A has characteristic diffraction peaks at the following 2θ angles: 8.86±0.20°, 10.50±0.20°, 11.38±0.20°, 13.18±0.20°, 16.04±0.20°, 16.48±0.20°, 17.80±0.20°, 19.96±0.20°, 20.36±0.20°, 20.72±0.20°, 21.92±0.20°, 22.34±0.20°, 23.00±0.20°, 24.42±0.20°, 26.12±0.20°, 26.86±0.20°, and 28.68±0.20°.
[0014] In some schemes of the present application, the XRPD spectrum data of the above-mentioned Form A is shown in Table 1:
[0015] Table 1 XRPD spectrum data of the crystal form of compound A of formula (I)
[0016] serial number 2θ angle (±0.20°) Relative strength (%) serial number 2θ angle (±0.20°) Relative strength (%) 1 8.86 22.9 14 22.34 53.6 2 10.50 46.0 15 23.00 10.2 3 11.38 27.8 16 23.80 7.9 4 13.18 17.9 17 24.42 13.7 5 15.68 8.6 18 24.64 9.2 6 16.04 13.8 19 25.28 5.4 7 16.48 17.9 20 26.12 12.8 8 17.80 35.0 21 26.86 21.8 9 19.54 9.0 22 27.38 4.1 10 19.96 18.4 23 28.68 10.5 11 20.36 30.5 24 30.16 5.6 12 20.72 100.0 25 32.46 5.5 13 21.92 11.5 / / / .
[0017] In some embodiments of the present application, the XRPD pattern of the above-mentioned Form A is as follows: Figure 1 shown.
[0018] In some embodiments of the present application, the differential scanning calorimetry (DSC) curve of the above-mentioned Form A has a starting point of an endothermic peak at 228.0±5°C.
[0019] In some embodiments of the present application, the DSC spectrum of the above-mentioned A crystal form is as follows: Figure 2 shown.
[0020] In some embodiments of the present application, the thermogravimetric analysis (TGA) curve of the above-mentioned crystal form A shows a weight loss of 0.2261% at 250.00±3°C.
[0021] In some embodiments of the present application, the TGA spectrum of the above-mentioned A crystal form is as follows: Figure 3 shown.
[0022] The present application also provides a method for preparing the crystal form A of the compound of formula (I), comprising:
[0023] 1) adding the compound of formula (I) into a mixed solvent of acetone and water;
[0024] 2) precipitate the solid, filter it and obtain Form A.
[0025] In some schemes of the present application, in the method for preparing the above-mentioned crystal form A, the volume ratio of acetone to water is selected from 1:1 to 10; preferably 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10 or a range consisting of any values.
[0026] In some schemes of the present application, in step 1) of the preparation method of the above-mentioned crystal form A, stirring is further included at a temperature selected from 25°C to 60°C; preferably 30 to 55°C; more preferably 40 to 50°C.
[0027] In some schemes of the present application, the preparation method 1) of the above-mentioned crystal form A further comprises stirring for a time selected from 1 hour to 72 hours; preferably 4 to 52 hours; more preferably 8 to 32 hours.
[0028] In some embodiments of the present application, in the method for preparing the above-mentioned crystal form A, the weight ratio of the compound of formula (I) to the solvent is selected from 1:1 to 30.
[0029] Some other solutions of the present application are obtained by any combination of the above variables.
[0030] On the other hand, the present application provides a crystalline composition comprising the crystal form of the present application, wherein the crystal form accounts for more than 50% by weight of the crystalline composition, preferably more than 80%, more preferably more than 90%, and most preferably more than 95%.
[0031] On the other hand, the present application provides a pharmaceutical composition, which includes a therapeutically effective amount of the crystal form of the present application, optionally including a pharmaceutically acceptable excipient.
[0032] The present application also provides a pharmaceutical composition, which includes a therapeutically effective amount of a crystalline composition of the crystalline form of the present application, optionally including a pharmaceutically acceptable excipient.
[0033] On the other hand, the present application provides use of the above-mentioned crystal form, its crystal form composition or its pharmaceutical composition in treating diseases responsive to TLR8 activation.
[0034] In another aspect, the present application provides a method for agonizing TLR8, comprising administering a therapeutically effective amount of the crystal form of the present application, a crystal form composition thereof, or a pharmaceutical composition thereof to an individual (preferably a human) in need thereof.
[0035] On the other hand, the present application provides the use of the crystal form of the present application, its crystal form composition or its pharmaceutical composition in the preparation of a drug for treating a disease responsive to TLR8 activation.
[0036] In some embodiments of the present application, the disease responsive to TLR8 activation is selected from viral infection.
[0037] In some embodiments of the present application, the viral infection is selected from hepatitis B virus (HBV) infection.
[0038] Technical Effects
[0039] The compounds of the present application have significant agonist activity on TLR8. The compounds of the present application show ideal TLR8 agonist activity and specific selectivity. The compounds of the present application show ideal TLR8 pathway-specific cytokine (IL-12p40, IFN-γ) induction activity. Mouse pharmacokinetic studies have shown that the compounds of the present application have moderate oral bioavailability and drug exposure, supporting oral administration. TLR8 agonists are immunomodulators, and excessive exposure may lead to excessive activation of the body's immune system, resulting in unforeseen side effects.
[0040] The A crystal form of the present application is easy to obtain, has good physical and chemical stability, and at the same time, has good pharmaceutical properties and is suitable for use as a drug, so it has high industrial application value and economic value.
[0041] Definition and Description
[0042] Unless otherwise specified, the following terms and phrases used herein are intended to have the following meanings. A particular phrase or term should not be considered to be uncertain or unclear in the absence of a special definition, but should be understood according to its ordinary meaning. When a trade name appears in this article, it is intended to refer to its corresponding commercial product or its active ingredient.
[0043] The intermediate compounds of the present application can be prepared by a variety of synthesis methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and equivalent substitution methods well known to those skilled in the art. Preferred embodiments include but are not limited to the examples of the present application.
[0044] The chemical reactions of the specific embodiments of the present application are carried out in a suitable solvent, which must be suitable for the chemical changes of the present application and the reagents and materials required. In order to obtain the compounds of the present application, it is sometimes necessary for those skilled in the art to modify or select the synthesis steps or reaction processes based on the existing embodiments.
[0045] The present application will be described in detail below through examples, which do not imply any limitation to the present application.
[0046] All solvents used in this application were commercially available and used without further purification.
[0047] This application uses the following abbreviations:
[0048]
[0049]
[0050] As used in this application, the powder X-ray diffraction (X-ray powder diffractometer, XRPD) of this application is detected by Dandong Haoyuan DX-2700BH X-ray diffractometer, light tube: Cu, kα,
[0051] As used in this application, the differential thermal analysis (DSC) of this application is detected by using a TA2500 differential scanning calorimeter.
[0052] As used in this application, the thermogravimetric analysis (TGA) of this application is detected using a TATGA550 thermogravimetric analyzer.
[0053] It should be noted that in the powder X-ray diffraction spectrum, the position of the peak or the relative intensity of the peak may vary due to factors such as the measuring instrument, measuring method / conditions, etc. For any specific crystal form, there may be an error in the position of the peak, and the measurement error of the 2θ value may be ±0.2°. Therefore, when determining each crystal form, this error should be taken into account, and the error is also within the scope of this application.
[0054] As used in this application, the relative intensity of the peaks in the XRPD can be calculated by peak height or peak area. The relative intensity in the "XRPD spectrum analysis data of the crystal form A of compound of formula (I) in Table 1" is calculated by peak height.
[0055] It should be noted that for the same crystal form, the position of the endothermic peak of DSC may be different due to factors such as the measuring instrument, measuring method / conditions, etc. For any specific crystal form, the position of the endothermic peak may have an error, which may be ±5°C or ±3°C. Therefore, when determining each crystal form, this error should be taken into account, and the error is also within the scope of this application.
[0056] It should be noted that for the same crystal form, the position of the weight loss temperature of TGA may be different due to factors such as the measuring instrument, measuring method / conditions, etc. For any specific crystal form, there may be an error in the position of the weight loss temperature, which may be ±5°C or ±3°C. Therefore, when determining each crystal form, this error should be taken into account, and the error is also within the scope of this application.
[0057] The word “comprise” or “comprises” and its English variations such as comprises or comprising should be construed as having an open and non-exclusive meaning, ie, “including but not limited to”.
[0058] The term "pharmaceutically acceptable" refers to those compounds, materials, compositions and / or dosage forms which, within the scope of sound medical judgment, are suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reaction or other problems or complications, commensurate with a reasonable benefit / risk ratio. "Pharmaceutically acceptable excipients" refer to inert substances that are administered together with the active ingredient and facilitate the administration of the active ingredient, including but not limited to any glidant, sweetener, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersant, disintegrant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier that is acceptable for use in humans or animals (e.g., livestock).
[0059] The term "pharmaceutical composition" refers to a mixture of one or more compounds of the present application or their salts and pharmaceutically acceptable excipients. The purpose of a pharmaceutical composition is to facilitate administration of the compounds of the present application to an organism.
[0060] The therapeutic dosage of the compound of the present application or its crystalline form may be determined, for example, based on the specific use of the treatment, the method of administering the compound, the health and condition of the patient, and the judgment of the prescribing physician. The ratio or concentration of the compound of the present application in the pharmaceutical composition may not be fixed, depending on a variety of factors, including dosage, chemical properties (e.g., hydrophobicity), and route of administration.
[0061] The dosage frequency of the crystal form described in the present application is determined by the needs of individual patients, for example, once or twice a day, or more times a day. Administration can be intermittent, for example, wherein during a period of several days, the patient receives a daily dose of the crystal form, and then during a period of several days or more days, the patient does not receive a daily dose of the crystal form.
[0062] The term "treatment" means administering the compound or formulation described herein to improve or eliminate a disease or one or more symptoms associated with the disease, and includes:
[0063] (i) inhibiting a disease or disease state, i.e. arresting its development;
[0064] (ii) ameliorating a disease or condition, even if causing regression of the disease or condition.
[0065] With respect to a drug or pharmacologically active agent, the term "therapeutically effective amount" refers to a sufficient amount of the drug or agent that is non-toxic but can achieve the desired effect. The determination of the effective amount varies from person to person, depending on the age and general condition of the recipient, and also on the specific active substance. The appropriate effective amount in each case can be determined by a person skilled in the art based on routine experiments.
[0066] Herein, singular terms include plural referents and vice versa unless the context clearly dictates otherwise. BRIEF DESCRIPTION OF THE DRAWINGS
[0067] Figure 1 The XRPD spectrum of the crystalline form A of compound of formula (I).
[0068] Figure 2 The DSC spectrum of the crystalline form A of compound of formula (I).
[0069] Figure 3 This is the TGA spectrum of the crystal form A of compound of formula (I). DETAILED DESCRIPTION
[0070] In order to better understand the content of this application, further description is given below in conjunction with specific embodiments, but the specific implementation methods are not limitations on the content of this application.
[0071] Example 1
[0072] Preparation of intermediate 1-10:
[0073]
[0074] Step A: Dissolve 1-1 (50 g, 412.54 mmol) and tetraethyl titanate (94.10 g, 412.54 mmol, 85.55 ml) in THF (500 ml) at 20-30 degrees Celsius, and then add 2-hexanone (41.32 g, 412.54 mmol, 51.01 ml). The reaction solution is heated to 65 degrees Celsius and stirred for 48 hours. The resulting reaction solution is directly used in the next step.
[0075] Step B: The step A reaction solution is cooled to room temperature and THF (1000 ml) is added, and allyl bromide (196.33 g, 1.62 mol) is added, and then zinc powder (53.06 g, 811.43 mmol) is slowly added in batches, and the reaction solution is stirred for 12 hours at 20 to 30 degrees Celsius under nitrogen protection. The reaction solution is filtered through diatomite, and the filtrate is added with saturated brine 100 ml, and after stirring, it is filtered through diatomite again, and the filtrate is spin-dried. The residue is dissolved with ethyl acetate (100 ml), and the organic phase separated is washed once with saturated brine (300 ml), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a crude product. The crude product is purified by column chromatography (SiO2, PE / EtOAc=15 / 1 to 5 / 1) to obtain 1-3. 1 H NMR (400MHz, CDCl3) δ5.96-5.75(m, 1H), 5.23-5.08(m, 2H), 3.20(s, 1H), 2.39-2.20(m, 2H), 1.74(br s, 1H), 1.56-1.42 (m, 2H), 1.40-1.15 (m, 14H), 0.96-0.86 (m, 3H).
[0076] Step C: 1-3 (15 g, 61.12 mmol) was dissolved in methanol (150 ml) and cooled to 0°C, and dioxane hydrochloride solution (4M, 91.68 ml) was slowly added at 0-20°C, and the reaction solution was stirred at 25°C for 2 hours. The reaction solution was directly concentrated under reduced pressure to obtain 1-4.
[0077] Step D: 1-4 (hydrochloride, 13 g, 73.15 mmol) and sodium bicarbonate (55.31 g, 658.36 mmol) were dissolved in dioxane (90 ml) and H2O (60 ml), cooled to 0 degrees Celsius, and CbzCl (74.87 g, 438.91 mmol, 62.40 ml) was slowly added dropwise. The reaction solution was heated to 20 to 30 degrees Celsius and stirred for 2 hours, extracted twice with ethyl acetate, 100 ml each time, the organic phases were combined, washed once with saturated brine (150 ml), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a crude product. The crude product was purified by column chromatography (SiO2, PE / EtOAc=1 / 0 to 100 / 1) to obtain 1-5. 1 H NMR (400MHz, CDCl3) δ7.30-7.26 (m, 5H), 5.76-5.62 (m, 1H), 5.08-4.91 (m, 4H), 2.47-2.34 (m, 1H), 2.32-2.20 (m, 1H), 1.72-1.57 (m, 1H), 1.50-1.42 (m, 1H), 1.30-1.10 (m, 7H), 0.76-0.76 (m, 1H), 0.76-0.76 (m, 1H), 0.82 (t, J=7.0Hz, 2H).
[0078] Step E: 1-5 (20.8 g, 75.53 mmol) was dissolved in acetonitrile (100 ml), H2O (150 ml) and carbon tetrachloride (100 ml), cooled to 0 degrees Celsius, sodium periodate (64.62 g, 302.12 mmol) was slowly added, and then ruthenium trichloride trihydrate (394.99 mg, 1.51 mmol) was added, and the reaction solution was heated to 25 degrees Celsius and stirred for 2 hours. The reaction solution was filtered through diatomaceous earth, then extracted once with DCM (200 ml), the organic phase was washed once with saturated sodium sulfite aqueous solution (200 ml), and then washed once with saturated brine (200 ml), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain crude 1-6, which was directly used in the next step. 1 H NMR (400MHz, CDCl3) δ7.40-7.35 (m, 5H), 5.19 (s, 1H), 5.08 (s, 2H), 2.89 (br d, J=14.5Hz, 1H), 2.69 (br d, J=14.4Hz, 1H), 1.90-1.77 (m, 1H), 1.74-1.62 (m, 1H), 1.43-1.20 (m, 7H), 0.90 (t, J=6.9Hz, 3H).
[0079] Step F: 1-6 (20 g, 68.18 mmol) and triethylamine (10.35 g, 102.26 mmol, 14.23 ml) were dissolved in THF (250 ml), and isobutyl chloroformate (9.78 g, 71.59 mmol, 9.40 ml) was added dropwise at -10 degrees Celsius under nitrogen protection, and stirred at -10 to 0 degrees Celsius for 30 minutes. Ammonia water (63.70 g, 454.41 mmol, 70 ml, 25%) was then slowly added, and the reaction was stirred at 0 to 5 degrees Celsius for 30 minutes. The reaction solution was concentrated under reduced pressure, and then extracted once with ethyl acetate (200 ml), and the organic phase was washed twice with saturated brine, 100 ml each time, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a crude product. The crude product was purified by column chromatography (SiO2, PE / EtOAc=10 / 1 to 1 / 1) to obtain 1-7. 1 H NMR (400MHz, CDCl3) δ7.41-7.28(m, 5H), 5.62(br s, 1H), 5.30-5.12 (m, 2H), 5.11-5.01 (m, 2H), 2.76 (d, J=13.2Hz, 1H), 2.44 (d, J=13.3H z, 1H), 1.85-1.74 (m, 1H), 1.73-1.62 (m, 3H), 1.39-1.29 (m, 5H), 0.90 (t, J=7.0Hz, 3H). LCMS(ESI)m / z:293.3[M+H] + .
[0080] Step G: 1-7 (15.34 g, 52.47 mmol) and N,N-dimethylformamide dimethyl acetal (134.55 g, 1.13 mol, 150 ml) were stirred at 120 degrees Celsius for 2 hours, concentrated under reduced pressure, dissolved in acetic acid (250 ml), slowly added with hydrazine hydrate (25.75 g, 504.09 mmol, 25 ml, 98%), and stirred at 90 degrees Celsius for 2 hours under nitrogen protection. The reaction solution was concentrated under reduced pressure, H2O (400 ml) was added, and then extracted with DCM twice, 200 ml each time, and the organic phases were combined and washed twice with saturated brine, 200 ml each time, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain crude 1-8. 1 H NMR (400MHz, CDCl3) δ7.95 (s, 1H), 7.43-7.29 (m, 5H), 5.08 (s, 2H), 4.90 (br s, 1H), 3.42 (br d, J=13.9Hz, 1H), 3.12 (d, J=14.3Hz, 1H), 1.87-1.77 (m, 1H), 1.68-1.58 (m, 1H), 1.41-1.17 (m, 7H), 0.90 (brt, J=6.5Hz, 3H). LCMS(ESI)m / z:317.2[M+H]+ .
[0081] Step H: 1-8 (15.20 g, 48.04 mmol) and DIPEA (12.42 g, 96.08 mmol, 16.74 ml) were dissolved in DCM (160 ml), triphenylmethane (20.09 g, 72.06 mmol) was slowly added, and the reaction solution was stirred at 25 degrees Celsius for 2 hours. H2O (100 ml) was added to the reaction solution and the pH (7-8) was adjusted with 2N dilute hydrochloric acid, and then extracted once with 100 ml of DCM. The organic phase was washed twice with saturated brine, 100 ml each time, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain a crude product. The crude product was purified by column chromatography (SiO2, PE / EtOAc=20 / 1 to 5 / 1) to obtain 1-9. 1 H NMR (400MHz, CDCl3) δ7.89 (s, 1H), 7.37-7.27 (m, 14H), 7.18-7.07 (m, 6H), 5.72 (br s, 1H), 5.16-4.93 (m, 2H), 3.07 (d, J=14.2Hz, 1H), 2.90 (d, J=14.2Hz, 1H), 1.80-1.61 (m, 4H), 1.33 (s, 3H), 0.90-0.84 (m, 3H). LCMS(ESI)m / z:559.3[M+H] + .
[0082] Step I: 1-9 (12.75 g, 22.82 mmol) was dissolved in isopropanol (300 ml), Pd / C (6 g) was added under nitrogen protection, the suspension was vacuum degassed and replaced with hydrogen three times, and stirred at 25 degrees Celsius for 16 hours under a hydrogen atmosphere (15 psi). The reaction solution was filtered through celite and washed with 300 ml of DCM, and the filtrate was concentrated under reduced pressure to obtain 1-10. 1 H NMR (400MHz, CDCl3) δ7.91 (s, 1H), 7.37-7.28 (m, 9H), 7.17-7.11 (m, 6H), 2.87 (s, 2H), 1.45-1.24 (m, 6H), 1.12 (s, 3H), 0.92-0.84 (m, 3H). LCMS(ESI)m / z:425.2[M+H] + .
[0083] Synthesis of hydrochloride of compound of formula (I):
[0084]
[0085] Step A: Compound 1-10 (1.91 g, 4.50 mmol) and 1-11 (900 mg, 4.50 mmol) were dissolved in THF (9 ml), and DIPEA (9.00 mmol, 1.57 ml) was added. The mixture was stirred at 70 degrees Celsius for 3 hours under nitrogen protection. The reaction solution was concentrated under reduced pressure to obtain crude product 1-12. LCMS (ESI) m / z: 588.42 [M+H] + .
[0086] Step B: The crude product 1-12 (3.60 g, 6.12 mmol) and 2,4-dimethoxybenzylamine ((3.01 mg, 18.00 mmol, 2.71 ml) were dissolved in 1,4-dioxane (30 ml) and protected with nitrogen, and DIPEA (8.99 mmol, 1.57 ml) was added, and the mixture was stirred at 100 degrees Celsius for 12 hours. The reaction solution was separated by adding water (20 ml) and ethyl acetate (50 ml), and the organic phase was washed with saturated brine (20 ml), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (SiO2, DCM / MeOH=100 / 1 to 15 / 1) to obtain 1-13. LCMS (ESI) m / z: 719.7 [M+H] + .
[0087] Step C: Compound 1-13 (2.00 g, 2.78 mmol) and triethylsilane (970.50 mg, 8.35 mmol, 1.33 ml) were dissolved in TFA (41.81 ml) and stirred at 28 degrees Celsius for 12 hours. The reaction solution was directly concentrated under reduced pressure and purified by p-HPLC (column: Phenomenex luna C18 250*50mm*10μm; flowability: [water (0.05% HCl)-acetonitrile]; acetonitrile%: 10%-40%, 28min, 50%min) to obtain the hydrochloride of the compound of formula (I). 1 H NMR (400MHz, CD3OD) δ9.15(s,1H),8.90(s,1H),8.59(d,J=5.6Hz,1H),8.26(d,J=5.5Hz,1H),4.11(d,J=14.8Hz,1H),3.53(d,J= 14.9Hz, 1H), 2.60 (dt, J = 4.1, 12.8Hz, 1H), 1.79 (dt, J = 4.2, 12.8Hz, 1H), 1.58 (s, 3H), 1.52-1.19 (m, 4H), 0.92 (t, J = 7.2Hz, 3H). LCMS(ESI)m / z:327.1[M+H] + .
[0088] Example 2: Preparation of Crystalline Form A of Compound (I)
[0089] The hydrochloride salt (1.4 g) of the compound of formula (I) was added to water (50 ml), and the pH was adjusted to 9-10 with solid sodium carbonate, and then extracted twice with ethyl acetate, 50 ml each time. The extract was concentrated, and acetone (10 ml) and water (10 ml) were added to the concentrate. The mixture was stirred at 25°C for 1 hour, and the acetone (about 8 mL) was removed by concentration under reduced pressure. The mixture was stirred at room temperature (15-25 degrees Celsius) for about 1 hour, and solids precipitated. The solids were filtered, and the filter cake was dried in a vacuum oven (45°C, 16 hours) to obtain a white solid, which is the A crystal form. Figure 1 The XRPD spectrum of the crystalline form is shown. Figure 2 The DSC spectrum of the crystal form is shown. Figure 3 The TGA spectrum of this crystal form is shown.
[0090] Experimental Example 1: In vitro receptor binding activity screening experiment of human Toll-like receptor 7 (TLR7) and human Toll-like receptor 8 (TLR8)
[0091] HEK-Blue was used in this experiment TM hTLR7 (Cat. No.: hkb-htlr7) and HEK-Blue TM hTLR8 (Cat. No.: hkb-htlr8) cell line was purchased from InvivoGen. These two cell lines were constructed by stably co-transfecting hTLR7 or hTLR8 with the human embryonic kidney 293 cell line and inducing the expression of the secretory alkaline phosphatase (SEAP) reporter gene, in which the secretory embryonic alkaline phosphatase (SEAP) reporter gene was regulated by the IFN-β promoter. The promoter is fused with the NF-κB and AP-1 binding sites. hTLR7 or hTLR8 agonists activate NF-κB and AP-1 and induce the expression and secretion of secretory alkaline phosphatase (SEAP). QUANTI-Blue TM The expression of SEAP was detected by the reagent to identify the agonist activity of the compound on hTLR7 and hTLR8 receptors.
[0092] Experimental steps:
[0093] 1. Compounds were added to the cell plate in a 3-fold gradient, with a total of 10 concentrations (5000nM, 1667nM, 556nM, 185nM, 62nM, 21nM, 6.9nM, 2.3nM, 0.76nM, 0.25nM), with duplicate wells for each concentration. 1 microliter of DMSO was added to each negative control well.
[0094] 2. Take out the T150 cultured cells from the CO2 incubator, discard the cell culture supernatant, wash the cells once with Dulbecco's phosphate buffered saline (DPBS), add about 10mL of culture medium, then tap the cell culture bottle to detach the cells, and then use a pipette to gently blow the cell clusters evenly. Count the cells and adjust the cell suspension to 500,000 cells / mL with culture medium. Then add 100 microliters of diluted cells to each well of the 96-well plate containing the compound (50,000 cells / well).
[0095] 3. Incubate the compound and cells in a 37°C, 5% CO2 incubator for 24 hours.
[0096] 4. Compound activity detection: Take 20 μL of cell supernatant from each well after induction and add it to 180 μL QUANTI-Blue TM After incubation at 37°C for 1 hour, the optical density absorbance (OD) of each well at 650 nm was measured using a multifunctional microplate reader. 650 ).
[0097] 5. Cell activity detection: Follow the instructions of ATPlite 1Step and detect the luciferase signal (RLU) using a multifunctional microplate reader.
[0098] 6. Data analysis: Compound activity: OD650 values were analyzed using GraphPad Prism software, and compound dose-effect curves were fitted to calculate the EC of the compound. 50 value (half maximal effect concentration).
[0099] Experimental results: as shown in Table 2.
[0100] Table 2
[0101] Test compound <![CDATA[Human TLR8 EC 50 (μM)]]> <![CDATA[Human TLR7 EC 50 (μM)]]> The hydrochloride of the compound of formula (I) 0.003 33.33
[0102] Conclusion: The compounds of the present application exhibit ideal TLR8 agonist activity and have specific selectivity for TLR8 between TLR8 and TLR7.
[0103] Experimental Example 2: Peripheral Blood Mononuclear Cell Experimental Protocol
[0104] TLR8 is a type of receptor that senses exogenous pathogens in the innate immune system. It can recognize exogenous viral single-stranded RNA and cause the release of a series of cytokines, such as TNF-α, IL-12, and IFN-γ, to induce antiviral immune responses; TLR7 is another type of receptor that senses exogenous pathogens in the innate immune system. After being activated, it mainly produces antiviral cytokines such as IFN-α. In this experiment, potential compounds of TLR8 agonists were used to stimulate human peripheral blood mononuclear cells (hPBMCs). The levels of the above-mentioned TNF-α, IL-12p40, IFN-γ, and IFN-α were detected to reflect the activation effect of the compounds on the TLR8 receptor and the selectivity of TLR8 / TLR7.
[0105] Experimental steps:
[0106] 1. Collect fresh blood from healthy volunteers and use EDTA-K2 anticoagulation tube (Cat. No.: BD-8516542) for anticoagulation;
[0107] 2. Ficoll density gradient centrifugation was used to separate the hPBMC cells in the middle cloud layer, and the cells were washed twice with RPMI1640 (source: Gibco, catalog number: 224400-089) culture medium containing 10% serum. The cells were resuspended in culture medium to 10 ml and counted with a Vi-cell cell counter. The cell suspension concentration was adjusted to 2×10 6 / mL;
[0108] 3. Dissolve the compound to 100mM with DMSO, and dilute to 50mM and 2mM with DMSO respectively, as the initial concentration, and make 3-fold dilutions in sequence, that is, take 5μL of the previous concentration sample + 10μL DMSO; dilute 8 gradients; and then dilute 500 times with culture medium to prepare the compound working solution;
[0109] 4. In a U-bottom 96-well plate, 100 μL of hPBMC suspension and 100 μL of compound working solution were added to each well, with final concentrations of 2000 nM, 666.7 nM, 222.2 nM, 74.1 nM, 24.7 nM, 8.2 nM, 2.7 nM, and 0.9 nM, respectively. The samples were incubated for 24 hours, and the supernatant was collected and frozen at -20°C to be tested for TNF-α, IFN-gamma, and IL-12p40 cytokines; the final concentrations of another group of compound samples were 50 μM, 16.7 μM, 5.6 μM, 1.9 μM, 0.6 μM, 0.2 μM, 0.1 μM, and 0.02 μM, respectively. The samples were incubated for 24 hours, and the supernatant was collected and frozen at -20°C to be tested for IFN-alpha cytokines;
[0110] 5. Flow cytometric bead microarray (CBA) was used to detect IL-12p40, TNF-α, and IFN-γ in the supernatant; enzyme-linked immunosorbent assay (ELISA) was used to detect IFN-α in the cell supernatant.
[0111] 6. Data Analysis: Compound Activity: EC 50 The half-maximal effect concentration (EC) of the compound was calculated by fitting the compound dose-effect curve. 50 value.
[0112] Experimental results: as shown in Table 3.
[0113] Table 3
[0114]
[0115] Conclusion: The compounds of the present application have ideal TLR8 pathway-specific cytokine IL-12p40, TNF-α and IFN-γ induction activity, and relatively low induction activity for TLR7 pathway-specific cytokine IFN-α, showing ideal specific selectivity for TLR8 pathway stimuli.
[0116] Experimental Example 3: Pharmacokinetic Study in Mice
[0117] This experiment is designed to evaluate the pharmacokinetic behavior of the compound after a single intravenous injection or oral administration in mice. For intravenous administration, the test compound was prepared into a 0.5 mg / ml clear solution in a solvent of 5% DMSO / 5% polyethylene glycol-15 hydroxystearate / 90% water; for oral administration, the test compound was prepared into a 2 mg / ml suspension in a solvent of 0.5% sodium carboxymethylcellulose / 0.2% Tween 80 / 99.3% water.
[0118] The concentration of the test compound in plasma was determined by high performance liquid chromatography-tandem mass spectrometry (LC-MS / MS). The retention time of the compound and internal standard, chromatogram acquisition and chromatogram integration were processed by software Analyst (Applied Biosystems), and the statistics of the data were processed by software Watson LIMS (Thermo Fisher Scientific) or Analyst (Applied Biosystems).
[0119] Using WinNonlin TM Plasma concentrations were treated with a noncompartmental model using the pharmacokinetic software Version 6.3 (Pharsight, Mountain View, CA), and pharmacokinetic parameters were calculated using the linear-log trapezoidal method.
[0120] The pharmacokinetic parameters of the hydrochloride of the compound of formula (I) in mice at a dose of 1 mg / Kg by intravenous injection and 5 mg / Kg by oral gavage are shown in Table 4 below.
[0121] Table 4
[0122]
[0123] Experimental Example 4: Stability Test
[0124] 1. Test of influencing factors
[0125] Examination samples:
[0126] Compound A of formula (I)
[0127] 1) Photostability test
[0128] 2 samples are exposed to light (one is a 5-day exposure sample, the other is a 10-day exposure sample); 2 samples are exposed to light control (one is a 5-day exposure control sample, the other is a 10-day exposure control sample). The exposed samples are placed in a clean watch glass, spread into a thin layer, and covered with a quartz glass cover. The control samples are packaged in the same way as the exposed samples, but the outside of the watch glass is covered with aluminum film.
[0129] Examination conditions: light box.
[0130] The results of the photostability test are shown in Table 5.
[0131] Table 5 Results of photostability test
[0132]
[0133] The above results show that under light conditions, the test items at 5 days and 10 days have no significant changes compared with the initial values, indicating that crystal form A has good light stability.
[0134] 2) Temperature influence test
[0135] Each sample was placed in an open watch glass and placed under high temperature conditions (60°C) for examination.
[0136] The high temperature test results are shown in Table 6.
[0137] Table 6 High temperature (60°C) test results
[0138]
[0139] The above results show that under high temperature conditions, the test items at 5 days, 10 days and 30 days have no significant changes compared with the initial values, indicating that crystal form A has good high temperature stability.
[0140] 3) Humidity effect test
[0141] Each sample was placed in an open flat weighing bottle and placed under high humidity conditions (25°C / 92.5RH) for examination.
[0142] The high humidity test results are shown in Table 7.
[0143] Table 7 Results of the test on the effect of high humidity (25°C / 92.5%RH)
[0144]
[0145] The above results show that under high humidity conditions, the test items at 5 days, 10 days and 30 days have no significant changes compared with the initial values, indicating that crystal form A has good high humidity stability.
[0146] 2. Accelerated testing
[0147] Examination samples:
[0148] Compound A of formula (I)
[0149] Packaging:
[0150] Inner packaging: double-layer medicinal low-density polyethylene bag; outer packaging: aluminum foil bag.
[0151] Test conditions: 40℃±2℃ / 75±5%RH
[0152] The results of the accelerated test are detailed in Table 8.
[0153] Table 8 Accelerated test (40℃±2℃ / 75±5%RH) Research results
[0154]
[0155] Note: N / A means not tested.
[0156] XRPD results showed no significant change compared with the initial value at 3 months, indicating that Form A remained stable under accelerated test conditions.
Claims
1. A crystalline form of the compound of formula (I), whose X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 8.86±0.20°, 10.50±0.20°, 11.38±0.20°, 17.80±0.20°, 20.72±0.20°, 22.34±0.20°, 2. The crystalline form according to claim 1, wherein its X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 8.86±0.20°, 10.50±0.20°, 11.38±0.20°, 13.18±0.20°, 17.80±0.20°, 20.72±0.20°, 22.34±0.20°, and 26.86±0.20°.
3. The crystalline form according to claim 1, wherein the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 8.86±0.20°, 10.50±0.20°, 11.38±0.20°, 13.18±0.20°, 16.48±0.20°, 17.80±0.20°, 20.36±0.20°, 20.72±0.20°, 22.34±0.20°, 24.42±0.20°, and 26.86±0.20°.
4. The crystalline form according to claim 1, wherein the X-ray powder diffraction pattern has characteristic diffraction peaks at the following 2θ angles: 8.86±0.20°, 10.50±0.20°, 11.38±0.20°, 13.18±0.20°, 16.04±0.20°, 16.48±0.20°, 17.80±0.20°, 19.96±0.20°, 20.36±0.20°, 20.72±0.20°, 21.92±0.20°, 22.34±0.20°, 23.00±0.20°, 24.42±0.20°, 26.12±0.20°, 26.86±0.20°, and 28.68±0.20°.
5. The crystal form according to claim 1, whose XRPD pattern is shown in Figure 1.
6. The crystal form according to claim 1, wherein the differential scanning calorimetry curve thereof has a starting point of an endothermic peak at 228.0±5°C.
7. The crystal form according to claim 1, whose DSC spectrum is shown in Figure 2.
8. The crystal form according to claim 1, wherein the thermogravimetric analysis curve thereof shows a weight loss of 0.2261% at 250.00±3°C.
9. The crystal form according to claim 1, whose TGA spectrum is shown in Figure 3.
10. A method for preparing the crystal form according to any one of claims 1 to 9, include: 1) adding the compound of formula (I) into a mixed solvent of acetone and water; 2) precipitate the solid, filter it and obtain the crystal form.
11. The preparation method according to claim 10, wherein the volume ratio of acetone to water is selected from 1:1 to 10.
12. The preparation method according to claim 11, wherein the volume ratio of acetone to water is selected from 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:
10.
13. The preparation method according to claim 11, wherein the volume ratio of acetone to water is selected from 1:1 to 8.
14. The preparation method according to claim 11, wherein the volume ratio of acetone to water is selected from 1:5 to 7.
15. The preparation method according to claim 10, wherein step 1) further comprises stirring at a temperature selected from 25°C to 60°C.
16. The preparation method according to claim 10, wherein step 1) further comprises stirring at a temperature selected from 30°C to 55°C.
17. The preparation method according to claim 10, wherein step 1) further comprises stirring at a temperature selected from 40°C to 50°C.
18. The preparation method according to claim 10, wherein step 1) further comprises stirring for a time selected from 1 hour to 72 hours.
19. The preparation method according to claim 10, wherein step 1) further comprises stirring for a time selected from 4 hours to 52 hours.
20. The preparation method according to claim 10, wherein step 1) further comprises stirring for a time selected from 8 hours to 32 hours.
21. The preparation method according to claim 10, wherein the weight ratio of the compound of formula (I) to the solvent is selected from 1:1 to 30.
22. A crystal composition comprising the crystal form according to any one of claims 1 to 9, wherein the crystal form accounts for more than 50% of the weight of the crystal composition.
23. The crystalline composition according to claim 22, wherein the crystalline form accounts for more than 80% of the weight of the crystalline composition.
24. The crystalline composition according to claim 23, wherein the crystalline form accounts for more than 90% of the weight of the crystalline composition.
25. The crystalline composition according to claim 24, wherein the crystalline form accounts for more than 95% of the weight of the crystalline composition.
26. A pharmaceutical composition comprising a therapeutically effective amount of the crystalline form according to any one of claims 1 to 9 or the crystalline form composition according to any one of claims 22 to 25.
27. The pharmaceutical composition according to claim 26, further comprising a pharmaceutically acceptable excipient.
28. Use of the crystalline form according to any one of claims 1 to 9, the crystalline form composition according to any one of claims 22 to 25, or the pharmaceutical composition according to claim 26 or 27 in the preparation of a medicament for treating a disease responsive to TLR8 excitation.
29. The use according to claim 28, wherein the disease responsive to TLR8 agonism is selected from viral infection.
30. The use according to claim 29, wherein the viral infection is selected from Hepatitis B virus infection.
